论文部分内容阅读
cefprozil是一种新的头孢菌素,有关本品的早期临床试验(1992)以及Medline医学研究(1994)显示,本品仅发生皮疹等过敏反应.然而,市场销售后向FDA自发报告显示,22例血清病样反应(SSLR),6例Ste-vens-Johnson综合征,20例多形性红斑(EM).SSLR通常在使用本品后7～12天发生,开始伴有斑疹或荨麻疹,发热和关节痛.淋巴结病、肺部症状、水肿、嗜酸粒细胞增多及肝功检查异常等反应较少见.其症状轻重不等并可持续数周.与典型的血清病相比,青霉素类、头孢菌素类、大环内酯类或磺胺类引发的SSLR中尚未见严重的内脏器官病变和伴血管内皮补体和免疫球蛋白沉积的循环免疫复征.
cefprozil is a new cephalosporin, the early clinical trials of this product (1992) and Medline Medical Research (1994) showed that this product only rashes and other allergic reactions However, the market after the FDA spontaneous report shows that 22 Six cases of Stevens-Johnson syndrome, 20 cases of erythema multiforme (EM) .SSLR usually occurs 7 to 12 days after the use of this product, beginning with a rash or urticaria , Fever and arthralgia, lymphadenopathy, pulmonary symptoms, edema, eosinophilia and abnormal liver function tests and other reactions are rare.The symptoms vary in severity and can last for several weeks.Compared with the typical serum disease, Penicillins, cephalosporins, macrolides, or sulfonamide-initiated SSLR have not seen severe visceral organ lesions and circulating immune syndrome with deposition of vascular endothelial complement and immunoglobulins.